Novavax (NVAX) shares plummeted 5.03% in pre-market trading on Friday following a significant price target cut by JPMorgan. The healthcare company's stock faced immediate pressure after the investment bank lowered its price target on Novavax to $7 from $9, maintaining an Underweight rating on the shares.
JPMorgan's decision to reduce the price target comes despite Novavax's Q2 performance beating expectations. However, the details of the earnings beat and JPMorgan's specific concerns were not fully disclosed in the available information. The maintained Underweight rating suggests that the investment bank continues to hold a pessimistic view on Novavax's near-term prospects.
This price target reduction could signal broader concerns about Novavax's future performance and may influence other investors' perceptions of the stock. As the trading day progresses, it remains to be seen how this pre-market plunge will impact Novavax's overall performance and whether other analysts will adjust their outlooks on the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。